Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
The post Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System appeared first on MedCity News.
